The University of Iowa
The University of Iowa News Services Home News Releases UI in the News Subscribe to UI News Contact Us


100 Old Public Library
Iowa City IA 52242
(319) 384-0012; fax (319) 384-0024

Release: May 10, 2001

PHOTO OPPORTUNITY: Congressman Jim Leach and University of Iowa President Mary Sue Coleman view the robotics and laboratory areas at the Biocatalysis Division of Albany Molecular Research, Inc.


WHAT: An open house at Albany Molecular Research's (NASDAQ:AMRI) new 10,000 square-foot facility.

WHO: Invited guests include Iowa Congressman Jim Leach; University of Iowa President Mary Sue Coleman; and Albany Molecular Research, Inc. Vice President of Operations Jim Grates.

WHEN: 3 to 5 p.m., Monday, May 14. Ceremony and open house begins at 3:30 p.m. Lab tours for the media and dignitaries will run from 2:45 p.m. to 3:15 p.m. Photo and video opportunities will be available during this time as Congressman Leach and President Coleman view the division's robotics and laboratory areas. Guided tours for other invited guests will be available from 4 to 5 p.m.

WHERE: Albany Molecular Research Inc. Biocatalysis Division, University of Iowa Oakdale Research Park, 2660 Crosspark Road, Coralville.

WHY: The AMRI expansion project represents an investment of $3 million in facilities and equipment and is expected to support the addition of at least 25 new employees. The expansion was made possible through a partnership between AMRI, the City of Coralville, the University of Iowa Oakdale Research Park, and the Iowa Department of Economic Development.

ß AMRI is a leading chemistry research, drug discovery and development company focusing on applications for the life sciences industries. The company performs comprehensive chemistry research for many of the leading pharmaceutical and biotechnology companies and for its own internal research and development. Last year, AMRI placed second among Forbes magazine's "200 Best Small Companies in America" and fourth on Business Week's list of 100 top growth companies. AMRI acquired its Biocatalysis Division, formerly known as EnzyMed Inc. in 1999.